VYNE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
VYNE Therapeutics Inc is not a strong buy at the moment for a beginner, long-term investor. While the technical indicators show some bullish signals, the lack of recent news, no significant trading trends, and poor financial performance with declining net income and EPS suggest that this stock does not currently present a compelling long-term investment opportunity. The absence of Intellectia Proprietary Trading Signals further supports this conclusion.
The MACD is positive and contracting, suggesting mild bullish momentum. The RSI is neutral at 65.492, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Support is at 0.606, and resistance is at 0.644 and 0.655. Overall, the technical indicators suggest a mildly bullish trend.
Revenue increased by 54.76% YoY in Q4 2025, and gross margin remains strong at 100%.
Net income dropped significantly by -59.77% YoY, and EPS declined by -60.71% YoY. No recent news or significant insider/hedge fund activity. No recent congress trading data.
In Q4 2025, revenue increased to $130,000 (up 54.76% YoY), but net income dropped to -$4,837,000 (down -59.77% YoY), and EPS declined to -0.11 (down -60.71% YoY). Gross margin remained at 100%.
No recent analyst rating or price target changes available.
